Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
IntroductionSemaglutide shows significant performance on weight reduction in several clinical trials. However, it is not clear what kind of administration frequency or dosage will achieve better effects. This study aims to explore the different therapeutic effect of semaglutide on weight control und...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1132004/full |
| _version_ | 1797793626916388864 |
|---|---|
| author | Rui Zhang Rui Zhang Qin-chuan Hou Qin-chuan Hou Bing-hong Li Bing-hong Li Ling Deng Yu-mei Yang Ting-xin Li Xiao-qin Yao Liang-liang Yang Xi-long Lin Yi-qian Liao Lin Wang Yu-ping Liu Jing Tan Zheng-wei Wan Ping Shuai Ping Shuai Ping Shuai |
| author_facet | Rui Zhang Rui Zhang Qin-chuan Hou Qin-chuan Hou Bing-hong Li Bing-hong Li Ling Deng Yu-mei Yang Ting-xin Li Xiao-qin Yao Liang-liang Yang Xi-long Lin Yi-qian Liao Lin Wang Yu-ping Liu Jing Tan Zheng-wei Wan Ping Shuai Ping Shuai Ping Shuai |
| author_sort | Rui Zhang |
| collection | DOAJ |
| description | IntroductionSemaglutide shows significant performance on weight reduction in several clinical trials. However, it is not clear what kind of administration frequency or dosage will achieve better effects. This study aims to explore the different therapeutic effect of semaglutide on weight control under the diverse administration circumstances.MethodsThe PubMed, Embase, Web of Science, Cochrane Library, and the Clinical Trials.gov were searched from inception until 6 June, 2022 to include randomized controlled trials evaluating the Efficacy and safety of subcutaneous semaglutide in overweight or obese adults. Random effects or fixed effects model was conducted based on the heterogeneity among trials. Subgroup analysis was performed to identify the detailed effects under different intervention situations.Results and discussionOur study included 13 RCTs involving 5,838 participants with 3,794 ones in semaglutide group and 2,044 in placebo group. Semaglutide was associated with a significant reduction on weight loss related outcomes, including the absolute value of weight loss (WMD -8·97, 95% CI -10·73 to -7·21), percentage of weight loss (WMD -10·00, 95% CI -11·99 to -8·00), body mass index (WMD-3·19, 95% CI -4·02 to -2·37) and waist circumference (WMD -7·21,95% CI -8·87 to -5·56). Subgroup analyses illustrated participants with high weekly dosage, long-term treatment duration and severe baseline BMI (Class II obesity) had a more remarkably decreasing on the main outcomes of weight loss (P for interaction<0·05). Total adverse reactions occurred more frequently in the daily administration group than that in the weekly group (P for interaction =0·01). During the treatment, the incidence rate of hypoglycemia was higher in the group without lifestyle intervention compared with that with lifestyle intervention (P for interaction =0·04). Interpretation Subcutaneous semaglutide had significant benefits on weight loss with reasonable safety in overweight or obese adults. Moreover, additional benefits on cardiometabolic profiles were also seen. We recommended semaglutide treatment to be coupled with lifestyle interventions, and target dose of 2·0 mg or more subcutaneously once weekly. Clinicians can choose suitable treatment schemes based on diverse individual situations.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=337099, identifier PROSPERO (CRD42022337099). |
| first_indexed | 2024-03-13T02:51:03Z |
| format | Article |
| id | doaj.art-fb36e515c5c7463ba0f56f6a450e94c7 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-13T02:51:03Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-fb36e515c5c7463ba0f56f6a450e94c72023-06-28T13:12:12ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-06-011410.3389/fendo.2023.11320041132004Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trialsRui Zhang0Rui Zhang1Qin-chuan Hou2Qin-chuan Hou3Bing-hong Li4Bing-hong Li5Ling Deng6Yu-mei Yang7Ting-xin Li8Xiao-qin Yao9Liang-liang Yang10Xi-long Lin11Yi-qian Liao12Lin Wang13Yu-ping Liu14Jing Tan15Zheng-wei Wan16Ping Shuai17Ping Shuai18Ping Shuai19Department of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Public Health, Southwest Medical University, Luzhou, ChinaDepartment of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Public Health, Southwest Medical University, Luzhou, ChinaDepartment of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaChinese Evidence-based Medicine Center and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Health Management & Physical Examination, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Public Health, Southwest Medical University, Luzhou, ChinaSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaIntroductionSemaglutide shows significant performance on weight reduction in several clinical trials. However, it is not clear what kind of administration frequency or dosage will achieve better effects. This study aims to explore the different therapeutic effect of semaglutide on weight control under the diverse administration circumstances.MethodsThe PubMed, Embase, Web of Science, Cochrane Library, and the Clinical Trials.gov were searched from inception until 6 June, 2022 to include randomized controlled trials evaluating the Efficacy and safety of subcutaneous semaglutide in overweight or obese adults. Random effects or fixed effects model was conducted based on the heterogeneity among trials. Subgroup analysis was performed to identify the detailed effects under different intervention situations.Results and discussionOur study included 13 RCTs involving 5,838 participants with 3,794 ones in semaglutide group and 2,044 in placebo group. Semaglutide was associated with a significant reduction on weight loss related outcomes, including the absolute value of weight loss (WMD -8·97, 95% CI -10·73 to -7·21), percentage of weight loss (WMD -10·00, 95% CI -11·99 to -8·00), body mass index (WMD-3·19, 95% CI -4·02 to -2·37) and waist circumference (WMD -7·21,95% CI -8·87 to -5·56). Subgroup analyses illustrated participants with high weekly dosage, long-term treatment duration and severe baseline BMI (Class II obesity) had a more remarkably decreasing on the main outcomes of weight loss (P for interaction<0·05). Total adverse reactions occurred more frequently in the daily administration group than that in the weekly group (P for interaction =0·01). During the treatment, the incidence rate of hypoglycemia was higher in the group without lifestyle intervention compared with that with lifestyle intervention (P for interaction =0·04). Interpretation Subcutaneous semaglutide had significant benefits on weight loss with reasonable safety in overweight or obese adults. Moreover, additional benefits on cardiometabolic profiles were also seen. We recommended semaglutide treatment to be coupled with lifestyle interventions, and target dose of 2·0 mg or more subcutaneously once weekly. Clinicians can choose suitable treatment schemes based on diverse individual situations.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=337099, identifier PROSPERO (CRD42022337099).https://www.frontiersin.org/articles/10.3389/fendo.2023.1132004/fullsemaglutideoverweightobesemeta-analysissubgroup |
| spellingShingle | Rui Zhang Rui Zhang Qin-chuan Hou Qin-chuan Hou Bing-hong Li Bing-hong Li Ling Deng Yu-mei Yang Ting-xin Li Xiao-qin Yao Liang-liang Yang Xi-long Lin Yi-qian Liao Lin Wang Yu-ping Liu Jing Tan Zheng-wei Wan Ping Shuai Ping Shuai Ping Shuai Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials Frontiers in Endocrinology semaglutide overweight obese meta-analysis subgroup |
| title | Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials |
| title_full | Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials |
| title_fullStr | Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials |
| title_full_unstemmed | Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials |
| title_short | Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials |
| title_sort | efficacy and safety of subcutaneous semaglutide in adults with overweight or obese a subgroup meta analysis of randomized controlled trials |
| topic | semaglutide overweight obese meta-analysis subgroup |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1132004/full |
| work_keys_str_mv | AT ruizhang efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT ruizhang efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT qinchuanhou efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT qinchuanhou efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT binghongli efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT binghongli efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT lingdeng efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT yumeiyang efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT tingxinli efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT xiaoqinyao efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT liangliangyang efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT xilonglin efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT yiqianliao efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT linwang efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT yupingliu efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT jingtan efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT zhengweiwan efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT pingshuai efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT pingshuai efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials AT pingshuai efficacyandsafetyofsubcutaneoussemaglutideinadultswithoverweightorobeseasubgroupmetaanalysisofrandomizedcontrolledtrials |